C-3QK2Restem
UMPCs, NK cells, immune modulation
modulatingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-3QK2
C-3QK2C-3QK2UMPCs, NK cells, immune modulation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Restem UMPCs, NK cells, immune modulation
Restem is advancing cell-based therapeutics intended to treat inflammatory-driven diseases by modulating immune response. Its proprietary platforms use Umbilical Cord Lining Modified Progenitor Cells and Activated Natural Killer Cells to support immune modulation and tissue repair. The site states Restem has 17 years of research, a leading IP portfolio, and end-to-end manufacturing capabilities for off-the-shelf cellular therapeutics. Restem-L demonstrated clinical benefit in Idiopathic Inflammatory Myopathies and received FDA Fast Track and Orphan Drug Designations as the company prepares for Phase 2/3 clinical trials.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Restem — Translational · Bottom quartile. Derived deterministically from 8 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic